Drug Target Insights call for papers from Dr Monica Milani

Dear colleagues,

I would like to invite you to submit a paper to Drug Target Insights – one of the most successful journals published by Libertas Academica, with a view factor of more than 70,000.

Drug Target Insights welcomes manuscripts reporting original and unpublished research regarding any aspect of the field of clinical therapeutics. More specifically, topics can range from the description molecular drug targets to the patients’ perspective on a particular therapeutic treatment. There is no restriction on the pathology under study.

All papers will be refereed within a peer-review system. Reviewers are experts in the field and will provide comments in a timely manner. Your paper will be indexed by the following databases: Embase, Google scholar, CAS, and DOAJ. Most importantly, in the event that your research is NIH funded, your paper will be also added to the Pubmed database.

Getting your paper published in an open access journal, such as Drug Target Insights, will benefit both you and the scientific community. You will benefit by making your research visible to the widest possible scientific audience. The scientific community will benefit from the fact that anyone will be able to learn about the latest discoveries in the field at no cost. When information is available to everybody, progress proceeds at the fastest pace.

In short, publishing in Drug Target Insights provides you with the following advantages:

• Full open access: everyone can read your article and you retain copyright in it
• Publishing decision within 2 weeks of submission
• Your paper will not be rejected due to lack of space and will be published immediately on acceptance
• Prompt and fair peer review from two expert peer reviewers
• Frequent updates on your paper’s status
• Friendly responsive staff

Aims and scope:

Drug Target Insights is a journal that publishes papers in all areas of drug treatment targets.

What a previous author said:

"I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely."

In summary:

The advantages of a younger journal such as Drug Target Insights are numerous but in essence allow us a greater flexibility and responsiveness to authors and readers that older journals cannot match.

Yours sincerely,
Dr Monica Milani

Editor-in-Chief
Drug Target Insights